Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: A case series on an escalating issue impacting patient safety

Leukemia and Lymphoma

Volumn 55, Issue 12, 2014, Pages 2813-2816

  Saavedra, Domingo ^a   Vizcarra, Fabiola ^a  

^a Fundación Colombiana de Cancerología   (Colombia)

Author keywords

BCR ABL; Chronic myeloid leukemia; Imatinib

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BONE PAIN; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; DEHYDRATION; DIARRHEA; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDEMA; ERYTHEMA; FEMALE; HUMAN; LEUKOPENIA; MALE; MIDDLE AGED; MYALGIA; NAUSEA; PATIENT SAFETY; PRURITUS; RASH; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; YOUNG ADULT; AGED; DRUG SUBSTITUTION; LEUKEMIA, MYELOID, CHRONIC-PHASE; MEDICINAL CHEMISTRY; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHEMISTRY, PHARMACEUTICAL; DRUG SUBSTITUTION; FEMALE; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84911369696     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.893302     Document Type: Article

References (10)

1. Glivec (imatinib mesylate) [prescribing information]. Basel, Switzerland: Novartis Pharma AG; 2008.
2. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. Blood 2009; 114(Suppl. 1): Abstract 1126.
3. Kefalas CH, Ciociola AA. The FDA's generic-drug approval process: similarities to and dif erences from brand-name drugs. Am J Gastroenterol 2011;106:1018-1021.
4. US Food and Drug Administration/Center for Drug Evaluation and Research, Of ce of Generic Drugs. Abbreviated New Drug Application (ANDA): Generics. 2010; 2011. Available from: www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/default.htm
5. Choufai Z. Hematologic relapse after 2 years on a non-authorized copy version of imatinib in a patient with chronic myeloid leukemia in chronic phase: a case report. Case Rep Oncol 2010; 3: 272-276.
6. Asfour IA, Elshazly SA. Changing therapy from Glivec to a " copy " imatinib results in a worsening of chronic myeloid leukemia disease status: two case reports. Cases J 2009;2:9342.
7. Mattar M. Failure of copy Imatib (CIPLA, India) to maintain hematologic and cytogenetic responses in chronic myeloid leukemia in chronic phase. Int J Hematol 2010;91:104-106.
8. Goubran HA.Failureofanon-authorizedcopyproducttomaintain response achieved with imatinib in a patient with chronic phase chronic myeloid leukemia: a case report. J Med Case Reports 2009;3:1-3.
9. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
10. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-1707.